Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid

J Lipid Res. 2013 Dec;54(12):3403-18. doi: 10.1194/jlr.M042051. Epub 2013 Oct 1.

Abstract

We recently reported that levels of unsaturated lysophosphatidic acid (LPA) in the small intestine significantly correlated with the extent of aortic atherosclerosis in LDL receptor-null (LDLR⁻/⁻) mice fed a Western diet (WD). Here we demonstrate that WD increases unsaturated (but not saturated) LPA levels in the small intestine of LDLR⁻/⁻ mice and causes changes in small intestine gene expression. Confirmation of microarray analysis by quantitative RT-PCR showed that adding transgenic tomatoes expressing the apoA-I mimetic peptide 6F (Tg6F) to WD prevented many WD-mediated small intestine changes in gene expression. If instead of feeding WD, unsaturated LPA was added to chow and fed to the mice: i) levels of LPA in the small intestine were similar to those induced by feeding WD; ii) gene expression changes in the small intestine mimicked WD-mediated changes; and iii) changes in plasma serum amyloid A, total cholesterol, triglycerides, HDL-cholesterol levels, and the fast-performance liquid chromatography lipoprotein profile mimicked WD-mediated changes. Adding Tg6F (but not control tomatoes) to LPA-supplemented chow prevented the LPA-induced changes. We conclude that: i) WD-mediated systemic inflammation and dyslipidemia may be in part due to WD-induced increases in small intestine LPA levels; and ii) Tg6F reduces WD-mediated systemic inflammation and dyslipidemia by preventing WD-induced increases in LPA levels in the small intestine.

Keywords: 6F peptide; apolipoprotein A-I mimetic peptides; atherosclerosis; genetically engineered tomato plants; lysophosphatidic acid.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoprotein A-I / metabolism
  • Diet / adverse effects*
  • Dyslipidemias / blood
  • Dyslipidemias / etiology*
  • Dyslipidemias / metabolism
  • Dyslipidemias / prevention & control*
  • Female
  • Gene Expression Regulation / drug effects
  • Inflammation / blood
  • Inflammation / etiology
  • Inflammation / metabolism
  • Inflammation / prevention & control
  • Intestine, Small / drug effects
  • Intestine, Small / metabolism*
  • Lysophospholipids / administration & dosage
  • Lysophospholipids / blood
  • Lysophospholipids / metabolism*
  • Lysophospholipids / pharmacology
  • Mice
  • Peptidomimetics / metabolism*
  • Plants, Genetically Modified
  • Receptors, LDL / deficiency
  • Solanum lycopersicum / genetics*
  • Western World

Substances

  • Apolipoprotein A-I
  • Lysophospholipids
  • Peptidomimetics
  • Receptors, LDL
  • lysophosphatidic acid